Notice of Availability of Nicotine Research Cigarettes through NIDA's Drug Supply Program

Notice Number: NOT-DA-13-002

Updates: The following updates relating to this announcement have been issued:

  • January 24, 2014 - See Notice NOT-DA-14-004, which replaces this Notice to update the catalog of research cigarettes and ordering guidelines from the NIDA Drug Supply Program.

Key Dates
Release Date: October 5, 2012

Related Announcements
PAR-12-266, PAR-12-267, PAR-12-268, RFA-DA-13-003

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

This Notice communicates the availability and procedures for acquisition of nicotine research cigarettes (NRC) through the NIDA Drug Supply Program (DSP). Information provided in this Notice will help the NIDA DSP and investigators effectively plan for the use of NRC and for responses to Funding Opportunity Announcements.

The NIDA DSP facilitates investigators' research by providing chemicals, including some chemicals needed for tobacco-related research, as well as research probes that are either unavailable, difficult to obtain, or very expensive for researchers to buy. Additionally, this program provides analytical services for analyses of researchers' experimental samples. Guidelines for U.S. research investigators to order from the DSP can be found here: http://www.drugabuse.gov/sites/default/files/files/OrderingGuidelinesUS.pdf.

Limited quantities of nicotine research cigarettes (NRC) manufactured through NIDA DSP are available to the research community under specified parameters for content of nicotine, menthol, and tar. The NIDA DSP will consider requests for its current inventory of NRC from researchers funded through the NIH to conduct tobacco science research. When needs are outside of the current inventory, additional NRC may be manufactured and made available to approved researchers if funds become available. To facilitate planning for either usage of the current inventory of NRC, or future manufacturing needs, the NIDA DSP requests that researchers requiring the use of NRC who may need NRC from NIDA DSP send an email request with the following information: 1) anticipated total number of each type of NRC needed, 2) the requested timeline and amounts for initial receipt, and 3) requested timeline of replenishment of each type of NRC.

Characteristics of the NRC inventory are described in the following table:

Type

Nicotine Content, mg/g

Nicotine Yield, mg/cigarette

Tar Yield, mg/cigarette

RN-HV

0.45

0.019

3.5

RN-HV-Men

0.43

0.016

3.3

RN

0.42

0.026

8.4

RN-Men

0.40

0.036

8.1

RN-HT

0.46

0.037

13.7

RN-HT-Men

0.44

0.024

12.1

RN-HT-Men

0.47

0.034

13.5

RN

1.34

0.072

8.2

RN-Men

1.33

0.074

8.0

RN

2.59

0.100

9.1

RN-Men

2.45

0.136

7.9

RN-HT-Men

2.54

0.154

14.2

RN

5.71

0.282

8.6

RN-Men

5.75

0.293

8.6

RN

5.87

0.321

12.1

RN-Men

5.89

0.238

8.3

RN-HT

7.93

0.652

14.8

RN-HT-Men

5.78

0.364

13.9

RN

11.67

0.660

13.5

RN-Men

12.80

0.634

9.8

CN

16.63

0.832

10.4

CN

15.82

0.680

10.1

CN-Men

16.08

0.748

10.1

CN-HT-Men

15.19

1.009

16.4

LTNR

24.79

1.654

16.3

LTNR-Men

25.60

1.187

12.3


*Legend:

RN-HV

Reduced Nicotine-High Ventilation

RN-HV-Men

Reduced Nicotine-High Ventilation Menthol

RN

Reduced Nicotine

RN-Men

Reduced Nicotine-Menthol

RN-HT

Reduced Nicotine-High Tar

RN-HT-Men

Reduced Nicotine-High Tar-Menthol

CN

Conventional Nicotine

CN-Men

Conventional Nicotine-Menthol

CN-HT-Men

Conventional Nicotine-High Tar-Menthol

LTNR

Low Tar/Nicotine Ratio

LTNR-Men

Low Tar/Nicotine Ratio-Menthol


Inquiries

Please direct DSP and NRC inquiries to:

Hari H. Singh, Ph.D.
Program Director
Drug Supply & Analytical Services
Chemistry & Physiological Systems Research Branch
Division of Basic Neuroscience & Behavioral Research
National Institute on Drug Abuse
National Institutes of Health
6001 Executive Boulevard, Room # 4282, MSC 9555
Bethesda, MD 20892-9555
Phone: (301) 435-1310
Fax: (301) 594-6943
E-mail: hsingh1@nida.nih.gov

Please direct other program inquiries related to Funding Opportunity Announcements (FOAs) through NIH or the NIH-FDA interagency partnership to the points of contact listed within the FOA.